JPH06227977A - Active oxygen eliminating agent - Google Patents

Abstract

PURPOSE:To obtain the subject eliminating agent useful for treating ischemic reperfusion, inflammation, etc., capable of specifically catching and eliminating OH radicals, etc., having excellent safety, comprising sesamin as an active ingredient. CONSTITUTION:The objective eliminating agent comprises sesamin and/or episesamin as an active ingredient. A dose of sesamin and/or episesamin is preferably 1-100mg/day per adult daily in the case of oral administration.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an in vivo active oxygen scavenger containing sesamin and / or episesamin, which has a specific biological scavenging effect on active oxygen having a strong biological activity.

[0002]

2. Description of the Related Art Although the essentiality of oxygen is easy to understand sensuously, it is also true that oxygen impairs living organisms. This oxygen damage is due to highly reactive oxygen reducing molecular species such as superoxide radical (O ₂ ⁻ ), hydrogen peroxide (H ₂ O ₂ ), OH radical (.OH) and excited molecular species such as singlet oxygen ( ¹ O ₂ ) is generated by oxidizing target molecules, and these molecular species are collectively called active oxygen.

Cell components, especially unsaturated fatty acid peroxy radicals (LOO.), Unsaturated fatty acid radicals (L.), unsaturated fatty acid hydroperoxides (LOOH), unsaturated fatty acid alkoxy radicals (LO), which are oxides of unsaturated lipids.・) Also shows the same action, and thus they are sometimes called active oxygen. In order to prevent this oxygen damage, organisms first keep the amount of active oxygen produced low, and then eliminate the active oxygen produced to prevent the oxidation of target molecules. However, when the suppression or elimination of active oxygen does not function sufficiently, or under physical or chemical environmental conditions in which active oxygen production increases, active oxygen oxidizes target molecules, which causes various disorders and diseases. Is triggered.

The mechanism for eliminating active oxygen in the living body is as follows:
Relatively long lifetime superoxide radical (O ₂ ^-)
, Hydrogen peroxide (H ₂ O ₂ ), unsaturated fatty acid hydroperoxide (LOOH) are eliminated by oxygen, and other active oxygen having a short life is thought to be eliminated by low molecular weight compounds such as ascorbic acid. For example superoxide radicals generated in the red blood cells (O ₂ ^-)
Is almost all superoxide dismutase (S
OD), hydrogen peroxide (H ₂ O ₂ ) is eliminated by catalase and peroxidase, and singlet oxygen (
¹ O ₂ ) is eliminated by β-carotene and tocopherol. Further, some scavenging low molecular weight compounds act not only on the active oxygen but also on the scavenging of organic radicals including lipid radicals, and therefore often act on the suppression of active oxygen production.

However, a specific scavenging low molecular weight compound has not yet been found for the OH radical, which is considered to have the highest reactivity among biological active oxygen and the greatest biological damage. In addition, since OH radicals react with almost all cell components at a rate close to diffusion-controlled, their lifetime is short, and it is considered that organisms cannot have a special mechanism for eliminating them.

[0006] when the damage in the components present in close proximity to the target molecule does not harm to the organism, but to some extent with the scavenging action of OH radicals, the organism rather superoxide radical (O ₂ ^-) and hydrogen peroxide It is believed that the elimination of (H ₂ O ₂ ) as completely as possible and the presence of the transition metal ion in the form of not catalyzing the formation of OH radicals suppresses the generation of OH radicals and prevents oxygen damage. Therefore, if an OH radical happens to occur, it reacts with the molecule that it encounters first, and if that molecule is important for the function of the cell, the cell will be damaged.
Radicals can be said to be the true causative agent of diseases caused by active oxygen.

The formation of this OH radical in the living body is represented by the following reaction formula (I):

[Chemical 1]

The superoxide radical (O ₂
^-) it is considered to be due to iron catalyst Harbor bypass reaction from superoxide radical (O ₂ ^-) of but disproportionation study of SOD or SOD-like active substance which catalyzes has been variously conducted, stability In addition to having a problem in that it does not directly eliminate OH radicals, none of them has been successfully commercialized.

[0009]

Therefore, the present invention is intended to provide an active oxygen scavenger having a direct scavenging action on active oxygen having a strong bioactive action, particularly OH radical.

[0010]

Means for Solving the Problems As a result of various studies to achieve the above object, the present inventors have found that sesamin and / or episesamin isolated from sesame seeds, sesame meal and sesame oil or obtained by synthesis But hydrogen peroxide (H
₂ O ₂ ), superoxide radical (O ₂ ⁻ ), organic radical, and singlet oxygen ( ¹ O ₂ ) are not trapped at all, but they specifically trap OH radical, and after sequestering sesamin and Degradation product of episesamin (2-
(3,4-methylenedioxyphenyl) -6- (3,4
-Dihydroxyphenyl) -cis-3,7-dioxabicyclo [3,3,0] octane and 2- (3,4-methylenedioxyphenyl) -6- (3,4-dihydroxyphenyl) -trans-3 , 7-dioxabicyclo [3,3,0] octane) is hydrogen peroxide (H ₂ O ₂ ),
Singlet oxygen ( ¹ O ₂ ), superoxide radical (O
₂ ^-), found OH radicals, the organic radical, to have a capturing ability of all lipid radicals. In other words, it reaches the target tissue where OH radicals exist without being decomposed,
The present invention has been completed by finding the completely ideal fact that after OH radical scavenging, it is converted into a compound having a total active oxygen scavenging ability.

Therefore, the present invention is intended to provide an in vivo active oxygen scavenger containing sesamin and / or episesamin, which has a specific scavenging action for OH radicals, as an active ingredient.

[0012]

[Detailed Description] Sesamin and episesamin used in the present invention are contained in sesame oil in an amount of about 0.5%, and are highly practical in terms of supply and highly safe. The sesamin and episesamin used in the present invention may be used alone or in combination. Also sesamin and /
Alternatively, an extract containing episesamin may be used.

As a method for obtaining sesamin and episesamin, which are the active ingredients of the present invention, and an extract containing the compound as a main component, the following procedure can be carried out. First, in order to obtain an extract containing a compound which is an active ingredient of the present invention as a main component from sesame oil, a compound which is substantially immiscible with sesame oil and which is an active ingredient of the present invention is extracted and dissolved. It can be obtained by extracting and concentrating with various organic solvents capable of Examples of such an organic solvent include acetone, methyl ethyl ketone, diethyl ketone, methanol, ethanol and the like.

In order to obtain an extract containing a compound as an active ingredient of the present invention as a main component, for example, sesame oil and any of the above-mentioned solvents are uniformly mixed and then allowed to stand at a low temperature, followed by centrifugation or the like. It is obtained by performing phase separation according to the method and evaporating and removing the solvent from the solvent fraction. More specifically, sesame oil is dissolved in 2 to 10 times, preferably 6 to 8 times the volume of acetone and left at -80 ° C overnight. As a result, the oil component becomes a precipitate, and the organic solvent is distilled off from the filtrate obtained by filtration to obtain an extract containing the compound of the present invention as a main component. Alternatively, it can be obtained by mixing sesame oil with hot methanol or hot ethanol, allowing to stand at room temperature, and removing the solvent from the solvent fraction by evaporation.

More specifically, sesame oil is added 2 to 10 times,
Preferably 5 to 7 volumes of hot methanol (50 ° C or higher)
Alternatively, mix with hot ethanol (50 ° C or more) and extract vigorously. Phase separation is performed according to a conventional method such as standing at room temperature or centrifugation, and the solvent is distilled off from the solvent fraction to obtain an extract containing the compound of the present invention as a main component. Supercritical gas extraction can also be used. In order to obtain each of the compounds of the present invention from this extract, the objective is to treat the extract according to a conventional method such as column chromatography, high performance liquid chromatography, recrystallization, distillation, and liquid-liquid exchange partition chromatography. The compound to be isolated may be isolated.

More specifically, the reversed-phase column (5
C ₁₀ ), using methanol / water (60:40) as an eluent, the above extract is separated by high performance liquid chromatography, the solvent is distilled off, and the obtained crystals are recrystallized with ethanol. As a result, sesamin and / or episesamin, which is the active ingredient of the present invention, can be obtained.

The sesame oil used may be a refined product, any crude product before the decoloring step in the process of producing sesame oil, and further sesame seeds or sesame meal (defatted sesame seeds, residual oil content 8 to 10%). Good. In this case, sesame seeds or sesame meal can be crushed if necessary, and then extracted by a conventional method using an arbitrary solvent, for example, the solvent described above for extraction from sesame oil. After separating the extraction residue,
An extract is obtained by removing the solvent from the extract by evaporation or the like.

From the sesame seed extract, sesame meal extract or crude sesame oil extract thus prepared, sesamin and / or episesamin, which are the active ingredients of the present invention, can be obtained in the same manner. It should be noted that sesamin obtained from spicy sponge has the same effect as sesamin obtained from sesame seeds, sesame meal and sesame oil, and these optically active substances are also included in the present invention. Furthermore, the compound which is the active ingredient of the present invention can be obtained from the by-product of the sesame oil production process.

The method for purifying sesamin and / or episesamin, which is the active ingredient of the present invention, and the method for obtaining an extract are not limited to these. Furthermore, the active ingredient compound of the present invention and the extract containing the compound of the present invention as the main components are not limited to those obtained from sesame oil, sesame meal, and sesame seeds, and natural products containing the compound of the present invention may be used. It is obvious that they can all be used, and examples thereof include Goka hide, paulownia wood, white fruit bark, hihatu, and spicy.

It is also possible to obtain sesamin and / or episesamin by synthesis. For example, sesamin and /
Alternatively, for episesamin, the method of Beroza et al. [J. Am. Chem.
Soc. 78 , 1242 (1986)]. The in vivo active oxygen scavenger of the present invention can be formulated together with commonly used carriers, auxiliaries, additives and the like, and oral and parenteral products are used as pharmaceuticals, quasi-drugs and
It can be used in the fields of cosmetics and foods and drinks. Oral preparations include tablets, capsules, granules, fine granules, syrups, etc., and parenteral preparations include ointments, creams, external preparations such as liquid preparations, intramuscular injection, subcutaneous injection, intravenous injection, etc. Injections and the like.

The diseases to which the present invention is applied include, for example, ischemia-reperfusion injury (myocardial injury, gastric mucosal injury, organ injury such as liver), inflammation (tissue injury based on increased vascular permeability, vascular endothelial injury, etc.), Atherosclerosis (endothelial cell injury, peroxidized L
DL production), digestive disorders (stress, shock, ischemic tissue damage), renal disorders (ischemic acute renal failure, glomerulonephritis, etc., methylguanidine production), endocrine disorders (diabetes, etc.), cataracts, cancer, Aging, autoimmune disorders, adult diseases,
UV disorders (sunburn), cosmetic disorders such as acne and spots, chronic skin diseases, allergic diseases, epilepsy, drug addiction diseases, Behcet's disease, etc. Peroxidation of cell membrane lipids by active oxygen, protein denaturation, nucleic acid disorders There are various diseases and symptoms caused by the above.

When these products are administered as a medicine, it varies depending on the purpose of administration and the condition of the recipient.
It is generally 1 to 100 mg / day for oral administration and 0.1 to 20 mg / day for parenteral administration. The compound of the present invention is admixed with a vehicle, a carrier, an excipient, an integrant, a preservative, a stabilizer, a flavoring agent and the like which are physiologically acceptable as pharmaceuticals in a required unit dosage form.

For example, when preparing an injectable preparation, a solubilizing agent for pharmaceuticals such as a nonionic surfactant can be used, and more specifically, the compound of the present invention can be used in an amount of 80 times the volume of POE (60). Heated castor oil or POE sorbitan monooleate and other nonionic surfactants are dissolved by heating,
It can be prepared by diluting with physiological saline. Further, if necessary, a tonicity agent, a stabilizer, a preservative, and a soothing agent may be appropriately added. As an external preparation, petrolatum, paraffin, oils and fats, lanolin, macrogol and the like can be used as a base, and an ointment, a cream and the like can be prepared by a usual method.

When the compound of the present invention is used as a food or drink, it may be in the form of the above-mentioned preparation, but it can be processed and produced by a general production method by adding a required amount of the compound of the present invention to a food material. At this time, the type and form of the food are not particularly limited. In addition, ingestion as a health food and functional food,
Since it is used for disease prevention and health maintenance, it is desirable to be ingested as a processed product containing 1 to 100 mg / day as an oral ingestion. Further, it can be used in combination with other active oxygen scavengers such as vitamin C, vitamin E, β-carotene and SOD. In particular, compounds having antioxidative properties such as vitamin C and vitamin E also have an action as a stabilizer of the compound of the present invention and are useful in combination, and vitamin E enhances the effect of the compound of the present invention. Can be expected.

The compound which is the active ingredient of the present invention has been
Since it is a compound found in foods, it is clearly superior in terms of safety. This is also 7 weeks old I
2.14 g / day / kg of sesamin for CR male mice
It was also apparent from the fact that no abnormal symptoms were observed after continuous administration (oral administration) for 2 weeks.

[0026]

EXAMPLES Next, the present invention will be described more specifically by way of examples.

Example 1. 1,1-diphenyl-2-pi
Crylhydrazyl (DPPH) reduction activity Brois method (MSBrois, Nature, 181, 1199-1200 (195
2) 0.1 mM DPPH ethanol solution according to 8))
25 μl of a sesamin / episesamin (6: 4) mixture or α-tocopherol (as a control compound) dissolved in dimethylsulfoxide (DMSO) at a predetermined concentration (dilution series) was added to the mixture, and after 20 minutes, at 516 nm. Absorbance was measured. This reducing activity is viewed by using the decrease in absorbance as an index of the scavenging activity of DPPH radicals, and as is clear from FIG. 1, this activity is not observed in the sesamin / episesamin (6: 4) mixture.
The addition concentration shown in FIG. 1 indicates the final concentration.

Example 2. Superoxide scavenging activity phenazine mesosulfate (0.6 mM) 5 μl, nitroblue tetrazolium (1 mM) 50 μl, phosphate buffer (0.1 M, pH 7.5) 370 μl mixed solution to a predetermined concentration in dimethyl sulfoxide (DMSO) (Dilution series)
25 μl of a sesamin / episesamin (6: 4) mixture, α-tocopherol, or quercetin (both as control compounds) dissolved in
The reaction was initiated by adding 50 μl of (1.6 mM), and inhibition (elimination activity) was observed with respect to an increase in absorbance (560 nm) due to the reduction of nitroblue tetrazolium by superoxide generated in this reaction system. Blank (solvent only)
Inhibition rate (%) was calculated from (1-a / A) × 100, where A is the increase in absorbance per unit time and A is the increase in absorbance per unit time when the compound is added. As shown in FIG. 2, sesamin / episesamin (6:
4) Superoxide scavenging activity was not observed in the mixture. The addition concentration shown in FIG. 2 indicates the final concentration.

Example 3. O by deoxyribose method
H radical scavenging activity When the reaction system used in this example generates an OH radical by a Fenton reaction and malondialdehyde (MDA) generated by the reaction of the OH radical and deoxyribose is reacted with thiobarbituric acid. It is based on the method of measuring the thiobarbituric acid-MDA adduct produced in the above.

That is, 0.1M phosphate buffer (pH 7.
Deoxyribose (1.43 mM) 69 dissolved in 4)
0 μl and FeSO ₄ / EDTA mixed solution (1 mM each) 10 μl
dimethyl sulfoxide (DMS)
O)) with a predetermined concentration (dilution series) dissolved in sesamin /
Add 100 μl of episesamin (6: 4) mixture or α-tocopherol (as control compound) and add 0.1
H ₂ O ₂ (5 dissolved in M phosphate buffer (pH 7.4)
200 μl of mM) is added, and the mixture is reacted at 28 ° C. for 16 hours.

After the reaction, trichloroacetic acid (2.8%) 0.
5 ml, 0.5 ml of thiobarbituric acid (1%) dissolved in 50 mM NaOH was added, boiled for 10 minutes, allowed to cool, and then the absorbance at 535 nm was measured. The inhibition rate (%) was determined from (1-a / A) × 100, where A is the absorbance of the blank (solvent only) and a is the absorbance of the compound added. As shown in FIG. 3, a strong OH radical scavenging activity was observed in the sesamin / episesamin (6: 4) mixture, and the I50 value giving 50% inhibition was approximately 3 μM. The addition concentration shown in FIG. 3 indicates the final concentration.

Example 4. Microsomal Lipid Peroxidation Inhibitory Activity The reaction system used in this example generates OH radicals by NADPH in rat liver microsomes,
Thiobarbituric acid-M generated when malondialdehyde (MDA) generated in the process of H radicals peroxidizing microsomal lipids is reacted with thiobarbituric acid
It is based on the method of measuring the DA adduct.

That is, 0.1M phosphate buffer (pH 7.
4) 0.5 ml with dimethyl sulfoxide (DMSO)
5 μl of sesamin, episesamin, or α-tocopherol (as a control compound) dissolved in a predetermined concentration (dilution series) was added to and dissolved in 0.1M phosphate buffer (pH 7.4). 0.5 ml of rat liver microsomes (1 mg protein / ml) was added and incubated at 37 ° C. for 5 minutes. The reaction is 0.1M phosphate buffer (pH
NADPH (1.5 mM) 0.25 dissolved in 7.4)
Start by adding ml, react at 37 ° C for 20 minutes, and stop the reaction by the method of Buege and Aust (J.
A.Buege and STDAust, Meth.Enzymol., 52,302-310, (1
978)) based thiobarbituric acid reagent was added.

After that, this was boiled for 10 minutes, the resulting precipitate was removed by centrifugation, and the absorbance at 535 nm was measured.
(1-a / A) × 10, where A is the absorbance of the blank (solvent only) and a is the absorbance of the compound added.
The inhibition rate (%) was calculated from 0. As shown in FIG. 4, sesamin and episesamin were found to have strong microsomal membrane lipid peroxidation inhibitory activity, and the I50 value for 50% inhibition was about 0.3 μM for both sesamin and episesamin. The addition concentration shown in FIG. 4 indicates the final concentration.

Example 5. Sesamin and episesamin
Dissolved 1,1-diphenyl-2-picrylhydrazine
(DPPH) Reduction-active sesamin and episesamin OH radical decomposition products were prepared. Sesamin or episesamin (10 mg / m 2) dissolved in acetone in 40 ml of 0.1 M phosphate buffer (pH 7.4)
1 ml of l) was added and dissolved, and then 50 ml of rat liver microsomes (3.99 mg protein / ml) suspended in 0.1 M phosphate buffer (pH 7.4) was added to the mixture at 37 ° C. for 10
Allowed to incubate for minutes. The reaction was NADPH (60 mM) 1 dissolved in 0.1 M phosphate buffer (pH 7.4).
Start by adding 0 ml.

After reacting at 37 ° C. for 2 hours, chloroform was used to extract sesamin, episesamin, a decomposed product of sesamin, and a decomposed product of episesamin from the reaction solution.
Isolation and purification by high performance liquid chromatography using DS-50 (Asahipak) according to a conventional method, and 2- (3,4
-Methylenedioxyphenyl) -6- (3,4-dihydroxyphenyl) -cis-3,7-dioxabicyclo [3,3,0] octane (Compound A) and 2- (3,4
-Methylenedioxyphenyl) -6- (3,4-cyhydroxyphenyl) -trans-3,7-dioxabicyclo [3,3,0] octane (Compound B) was identified. The DPPH reducing ability was measured according to Example 1. 0.1 mM
Compound A or B (concentration am in dimethyl sulfoxide (DMSO)) dissolved in 2 ml of ethanol solution of DPPH
M) was added in an amount of 75 μl, and after 20 minutes, the absorbance at 516 nm was measured. The DPPH reducing ability of the compound A or B was calculated by the following formula.

[0037]

[Equation 1]

X is 5 obtained by adding compound A or B
Absorbance at 16 nm. y is the absorbance at 516 nm obtained when no compound was added. A is the DPPH concentration in mM (0.1). D is the dilution ratio of the compound A or B solution in the reaction solution (2025/25). a is the concentration of compound A or B shown in mM. Compound A, B, D of sesamin or episesamin
The results of measuring the PPH reducing ability are shown in Table 1.

[0039]

Furthermore, when the microsomal lipid peroxidation inhibitory activity was measured according to Example 4, as shown in FIG. 5, the compounds A and B exhibited an activity equal to or higher than that of sesamin. From the above, sesamin and episesamin, which are OH radical selective scavengers, can be trapped and scavenged even for active radicals such as organic radicals and superoxide radicals and free radicals when metabolized in the target tissue in vivo. It became clear.

Example 6. Butter fat 1 from which butter milk has been removed by the agitating operation (churning) in the butter manufacturing process
2.4 g of the compound of the present invention was added to 00 g, and a kneading operation (working) was performed to obtain a butter containing the compound of the present invention having a uniform composition.

Example 7. 0.5 g of the compound of the present invention was mixed with 20.5 g of silicic acid anhydride, 79 g of corn starch was added thereto, and further mixed. Add 100 ml of 10% hydroxypropylcellulose / ethanol solution to this mixture.
Was added, kneaded in the usual manner, extruded and dried to obtain granules.

Example 8. 7 g of the compound of the present invention was mixed with 20 g of silicic acid anhydride, 10 g of microcrystalline cellulose, 3.0 g of magnesium stearate and 60 g of lactose were added and mixed, and the mixture was tableted by a single-shot tableting machine to give a diameter of 7 mm. , Tablets weighing 100 mg were produced.

Example 9. 2.5 g of the compound of the present invention is used as TO-10M (Nikko Chemicals) 2 which is a nonionic surfactant.
It was dissolved by heating in 00 g at 122 ° C., and 4.7975 l of sterilized physiological saline heated to 60 ° C. was added thereto and well stirred,
This was aseptically distributed into vials and sealed to prepare an injection.

Example 10. 7 g of propylene glycol is added to 53 g of purified water and heated to maintain the temperature at 70 ° C. (aqueous phase). The compound of the present invention 2 g, microcrystalline wax 1 g, beeswax 2 g, liquid paraffin 18 g, squalene 10
g, sorbitan sesquioleate 4g, and polyoxyethylene (20 mol) solibitan monooleate 1g were mixed, heated to 122 ° C and completely dissolved, and then kept at 70 ° C, and an appropriate amount of perfume and preservative was added. Mix (oil phase). While stirring the oil phase, the aqueous phase was gradually added to this to uniformly emulsify with a homomixer, and after emulsification, the mixture was cooled to 30 ° C. with stirring to prepare an emulsion.

Example 11. 0.5 g of the compound of the present invention and 0.5 g of vitamin C were mixed with 20 g of silicic acid anhydride, 79 g of corn starch was added thereto, and the mixture was further mixed. To this mixture was added 100 ml of a 10% hydroxypropylcellulose / ethanol solution, which was kneaded in the usual manner, extruded and dried to obtain granules.

Example 12 5 g of the compound of the present invention and 2 g of tocopherol acetate were mixed with 20 g of silicic acid anhydride, and 10 g of microcrystalline cellulose and magnesium stearate 3
g and lactose 60 g were added and mixed, and the mixture was tabletted by a single-shot tableting machine to produce tablets having a diameter of 7 mm and a weight of 100 mg.

[0048]

From the results of the examples, the active oxygen scavenger of the present invention containing sesamin and / or episesamin is
Ischemia / reperfusion injury (myocardial injury, gastric mucosal injury, organ injury such as liver), inflammation (vascular hyperpermeability, vascular endothelial cell injury,
Production of peroxidized LDL), digestive system diseases (stress, shock, ischemic tissue damage), renal disease (ischemic acute renal failure, methylguanidine production such as glomerulonephritis), endocrine disease (diabetes etc.), cataract etc. The active oxygen, which is the cause, is the most reactive among them, and specifically captures and eliminates OH radicals that do not have a defense mechanism in the living body, and after sesamin and / or episesamin is metabolized in the target tissue in the living body, It is clear that the present invention is extremely useful because the decomposed product thereof has the ability to trap and eliminate active radicals such as organic radicals and superoxide radicals as well as free radicals.

[Brief description of drawings]

FIG. 1 shows the reducibility of a sesamin / episesamin mixture and an α-tocopherol control to 1-diphenyl-2-picrylhydrazyl.

FIG. 2 is a sesamin / episesamin (6 :) for reduction of nitroblue tetrazolium by NADH.
4) Shows the inhibitory effect of the mixture, α-tocopherol control and quercetin control.

FIG. 3 is a sesamin / episesamin mixture and α-for the reaction of OH radicals with deoxyribose.
The inhibitory effect (OH radical scavenging effect) of the tocopherol control is shown.

FIG. 4 shows the inhibitory effect of sesamin, episesamin and α-tocopherol controls on the peroxidation of microsomal membrane lipids by OH radicals.

FIG. 5 shows the inhibitory effects of sesamin OH radical decomposition products (compound A), episesamin OH radical decomposition products (compound B) and sesamin on the peroxidation of microsomal membrane lipids by OH radicals.

Continuation of the front page (51) Int.Cl. ⁵ Identification code Office reference number FI Technical indication location A61K 31/34 ACV 7431-4C C07D 493/04 A 9165-4C (72) Inventor Masa Shimizu Kyoto Kyoto City Chukyo 14 Nishinokyo-Kurakucho, Ward

Claims (2)

[Claims] 1. An in vivo active oxygen scavenger containing sesamin and / or episesamin as an active ingredient. 2. The scavenger according to claim 1, wherein the active oxygen in the body is an OH radical.